New treatment approach for Fanconi anemia using enzymes
Official title: Evaluating a Novel Enzymatic Modality for the Treatment of Fanconi Anemia
Funded at Kinetiq Therapeutics LLC · NIH-11005464 · Data updated 2026-11-12
This study is looking at a new treatment for kids with Fanconi anemia that uses special enzymes to help reduce harmful substances in the body, aiming to improve their blood health and overall well-being.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinetiq Therapeutics LLC NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project start | August 20, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $306,870 |
| NIH project number | 1R43HL176246-01 |
| Project ID | NIH-11005464 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with Fanconi anemia.
✕Less likely to help
Patients with other forms of bone marrow failure or those outside the specified age range may not benefit from this research.
What this research studies
This research focuses on developing a novel enzymatic treatment for Fanconi anemia, a genetic disorder that leads to severe bone marrow failure and increased cancer risk in children. The study aims to explore how specific enzymes can counteract the toxic effects of aldehydes, which are harmful byproducts of DNA damage. By targeting these toxic substances, the research seeks to improve hematopoietic (blood-forming) function and overall patient health. The approach is innovative as it addresses the root causes of the disease rather than just managing symptoms.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that improves survival and quality of life for children with Fanconi anemia.
How similar studies have gone: While there have been emerging strategies for treating Fanconi anemia, this enzymatic approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Kinetiq Therapeutics LLC
Fort Worth, United States Active
Researchers
- Principal investigator: Cao, Mingju — Kinetiq Therapeutics LLC
- Study coordinator: Cao, Mingju
Related research
Other NIH-funded projects on the same topics.
-
In vivo gene repair to restore healthy hematopoiesis in Fanconi anemia
A study aims to repair faulty genes inside patients’ blood-forming cells to help people with Fanconi anemia regain healthy blood cell production.
-
Understanding genetic dependencies when Fanconi anemia pathway is lost
A study to find other genes or pathways that cancer cells rely on when the Fanconi anemia repair system is broken, with the aim of guiding future treatments.
-
Innovative cell and gene therapy approaches to treat Fanconi anemia
A Stanford-led project aims to develop safer cell and gene therapies to help people with Fanconi anemia who have bone marrow failure.
-
How cells detect DNA damage and activate ATR, ATM, and Fanconi anemia repair systems
Researchers are using high-resolution structural imaging to show how key repair proteins sense DNA damage, with relevance for people whose cancers come from DNA repair defects.
-
In vivo gene therapy for Fanconi anemia
A patient-focused overview of a potential in vivo gene therapy approach to correct Fanconi anemia, aiming to reduce the need for donor transplants.
-
Fanconi anemia: what happens inside cells
Researchers want to learn how proteins called REV7 and CHAMP1 change DNA repair in people with Fanconi anemia and related genetic syndromes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.